Document is current

Article History

Received: 4 February 2021

Accepted: 7 April 2021

First Online: 22 April 2021

Declarations

:

: Patient consent: All patients included in the EUSTAR database have signed an informed consent form in their EUSTAR center.Ethics approval: All contributing EUSTAR centers have obtained approval from their respective ethics committee for including a patient’s data in the EUSTAR database after the patient has given written informed consent. Ethical approval for this data collection and analysis was issued by the cantonal ethics (BASEC Nr. PB_2016-01515 and 2018-02165).

: All authors have agreed on the final version of the submitted paper.

: Norina Zampatti, Alexandru Garaiman, and Suzana Jordan: nothing to disclose.Rucsandra Dobrota has received grants/research support from Actelion and Pfizer, outside the submitted work.Mike Oliver Becker has received consultancy fees from Bayer and Amgen, outside the submitted work.Britta Maurer had grant/research support from AbbVie, Protagen, Novartis, congress support from Pfizer, Roche, Actelion, and MSD, and received consultancy fees from Boehringer Ingelheim, outside the submitted work. In addition, B. Maurer has a patent mir-29 for the treatment of systemic sclerosis registered.Oliver Distler has received consultancy fees from Acceleron Pharma, Amgen, AnaMar, Arxx Therapeutics, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer Ingelheim, Corbus Pharmacheuticals, ChemomAb, CSL Behring, Galapagos NV, Glenmark Pharmaceuticals, GSK, Horizon Pharmaceuticals, Inventiva, Italfarmaco, iQvia, Kymera Therapeutics, Lilly, Medac, Medscape, MSD, Novartis, Pfizer, Roche, Roivant Sciences, Sanofi, Serodapharm, Topadur, Target Bioscience and UCB, in the area of potential treatments of scleroderma and its complications, outside the submitted work. In addition, Prof. Distler had a project scoring fee from Abbvie and grants/research support from Kymera and Mitsubishi Tanabe Pharma. He also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143).Carina Mihai has received congress support from Actelion and Roche, and personal fees from Boehringer Ingelheim, Mepha, and MEDtalks Switzerland, outside the submitted work.